Skip to content
RADBIO logo

RADBIO Alternatives & Competitors

12 companies similar to RADBIO — Developing a therapeutic platform targeting TGF-beta, the "master regulator of f...

Companies similar to RADBIO

RiboNova, Inc. logo — alternative to RADBIO

RiboNova, Inc.

Focused on Mitochondrial Disease & other serious rare diseases. R007 is our P2 ready asset...

SonoThera logo — alternative to RADBIO

SonoThera

SonoThera is developing ultrasound-mediated nonviral genetic therapies.

Kelonia Therapeutics logo — alternative to RADBIO

Kelonia Therapeutics

Revolutionizing in vivo gene delivery to usher in a new era of genetic medicines.

Zelluna Immunotherapy logo — alternative to RADBIO

Zelluna Immunotherapy

Developing allogeneic TCR-NK therapies for solid tumors

Rival Readout

Competing with RADBIO? We do this properly.

10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.

Book a 7-day Readout
Janux Therapeutics logo — alternative to RADBIO

Janux Therapeutics

Developing unique immunotherapies that generate tumor-specific immune responses to attack...

A2 Biotherapeutics, Inc. logo — alternative to RADBIO

A2 Biotherapeutics, Inc.

Powerful & precise T cell therapy that attacks solid tumors while sparing normal cells.

Pliant Therapeutics logo — alternative to RADBIO

Pliant Therapeutics

We are transforming the lives of patients by developing best-in-class treatments for fibro...

MDI Therapeutics, Inc. logo — alternative to RADBIO

MDI Therapeutics, Inc.

Developing novel serpin-based therapies

Lisata Therapeutics, Inc. logo — alternative to RADBIO

Lisata Therapeutics, Inc.

Targeted Therapy Delivered

ImmunoBiochem Corporation logo — alternative to RADBIO

ImmunoBiochem Corporation

Improving patient outcomes through innovations in biological therapeutics

Hercules Pharmaceuticals logo — alternative to RADBIO

Hercules Pharmaceuticals

Driving Innovation in Non-Toxic Oral Therapies for Triple Negative Breast Cancer and Solid...

AlgiPharma AS logo — alternative to RADBIO

AlgiPharma AS

A biopharmaceutical company with a focus on developing its first drug candidate for patien...

About RADBIO

RADBIO is a biopharmaceutical startup focusing on developing a therapeutic platform targeting TGF-beta, known as the "master regulator of fibrosis." Fibrosis, a significant factor in the cause of death for many diseases, lacks effective treatments to halt or reverse its progression, despite existing drugs that can dela...

Business keywords

Therapeutic Platform, TGF-beta, Fibrosis Treatment, Genetic Engineering, Drug Development, Biomolecule Therapy, Research And Development, Biomarkers, Biopharmaceutical, Diagnosis, Solid Tumors, Neutralizing Biomolecule, Delivery Strategies

Frequently Asked Questions

Companies similar to RADBIO include RiboNova, Inc., SonoThera, Kelonia Therapeutics, Zelluna Immunotherapy, Janux Therapeutics. They work in Biotechnology and Pharmaceutical and share RADBIO's focus on solid tumors, biopharmaceutical and drug development.
Bounce Watch lists 12 companies that share RADBIO's industries and are closest to it in business tags, services, target customers, business model and size.
RADBIO is a biopharmaceutical startup focusing on developing a therapeutic platform targeting TGF-beta, known as the "master regulator of fibrosis." Fibrosis, a significant factor in the cause of death for many diseases, lacks effective treatments to halt or reverse its progression, despite existing drugs that can dela...

From the desk

Mapping a market? Start with a Rival Readout.

In 7 business days we read 10 rivals around RADBIO: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.

Compiled from the BounceWatch company index. We last looked at RADBIO on 27 Oct 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout